These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38225773)

  • 1. MRI-defined T3, clear mesorectal fascia mid-low rectal cancer: is neoadjuvant treatment necessary?
    Zeng Z; Li Z; Luo S; Huang L; Liang Z; Zheng X; Li W; Xiong L; Liu H; Kang L
    J Gastroenterol Hepatol; 2024 May; 39(5):858-867. PubMed ID: 38225773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI-defined high-risk rectal cancer patients: outcome comparison between neoadjuvant chemoradiotherapy plus TME and TME plus adjuvant chemotherapy or TME alone.
    Jia X; Xie P; Bi L; Meng X; Wang Z; Hong N; Wang Y
    Br J Radiol; 2021 Apr; 94(1120):20201221. PubMed ID: 33591799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avoidance of Overtreatment of Rectal Cancer by Selective Chemoradiotherapy: Results of the Optimized Surgery and MRI-Based Multimodal Therapy Trial.
    Ruppert R; Kube R; Strassburg J; Lewin A; Baral J; Maurer CA; Sauer J; Junginger T; Hermanek P; Merkel S;
    J Am Coll Surg; 2020 Oct; 231(4):413-425.e2. PubMed ID: 32697965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncological outcome after MRI-based selection for neoadjuvant chemoradiotherapy in the OCUM Rectal Cancer Trial.
    Ruppert R; Junginger T; Ptok H; Strassburg J; Maurer CA; Brosi P; Sauer J; Baral J; Kreis M; Wollschlaeger D; Hermanek P; Merkel S;
    Br J Surg; 2018 Oct; 105(11):1519-1529. PubMed ID: 29744860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer.
    Chen JN; Liu Z; Wang ZJ; Mei SW; Shen HY; Li J; Pei W; Wang Z; Wang XS; Yu J; Liu Q
    World J Gastroenterol; 2020 Jun; 26(21):2877-2888. PubMed ID: 32550762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of surgery alone versus surgery following preoperative chemoradiotherapy for early T3 rectal cancer: A propensity score analysis.
    Cho SH; Choi GS; Kim GC; Seo AN; Kim HJ; Kim WH; Shin KM; Lee SM; Ryeom H; Kim SH
    Medicine (Baltimore); 2017 Mar; 96(12):e6362. PubMed ID: 28328820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of the EMD/mesorectum ratio of T3 mid-low rectal cancer: A retrospective observational study.
    Gu C; Yang X; Zhang X; Zheng E; Deng X; Hu T; Wu Q; Bi L; Wu B; Su M; Wang Z
    Medicine (Baltimore); 2018 Nov; 97(48):e13468. PubMed ID: 30508974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total Mesorectal Excision Versus Local Excision After Favorable Response to Preoperative Chemoradiotherapy in "Early" Clinical T3 Rectal Cancer: A Propensity Score Analysis.
    Shin YS; Yu CS; Park JH; Kim JC; Lim SB; Park IJ; Kim TW; Hong YS; Kim KP; Yoon SM; Joo JH; Kim JH
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):136-144. PubMed ID: 28816139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 10. Pretreatment MRI-detected extramural venous invasion as a prognostic and predictive biomarker for neoadjuvant chemoradiotherapy in non-metastatic rectal cancer: a propensity score matched analysis.
    Yang SY; Bae H; Seo N; Han K; Han YD; Cho MS; Hur H; Min BS; Kim NK; Lee KY; Lim JS
    Eur Radiol; 2024 Jun; 34(6):3686-3698. PubMed ID: 37994967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing operative strategy from abdominoperineal resection to sphincter preservation in T3 low rectal cancer after downstaging by neoadjuvant chemoradiation: a preliminary report.
    Madbouly KM; Hussein AM
    World J Surg; 2015 May; 39(5):1248-56. PubMed ID: 25561197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
    Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
    [No Abstract]   [Full Text] [Related]  

  • 13. The influence of neoadjuvant chemoradiotherapy combined with lateral lymph nodes dissection or not on the local recurrence of low to intermediate-stage II/III rectal cancer.
    Li C; Luan J; Ji X; Wang X; Li J; Li X; Zhou Y
    J Surg Oncol; 2024 Feb; 129(2):273-283. PubMed ID: 37811551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of neoadjuvant treatment strategy on perioperative outcomes in locally advanced rectal cancer.
    McFeetors C; O'Connell LV; Choy M; Dundon N; Regan M; Joyce M; Meshkat B; Hogan A; Nugent E
    Colorectal Dis; 2024 Apr; 26(4):684-691. PubMed ID: 38424706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is neoadjuvant chemoradiotherapy always necessary for mid/high local advanced rectal cancer: A comparative analysis after propensity score matching.
    Zhang Y; Sun Y; Xu Z; Chi P; Lu X
    Eur J Surg Oncol; 2017 Aug; 43(8):1440-1446. PubMed ID: 28502421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robotic versus laparoscopic sphincter-saving total mesorectal excision for mid or low rectal cancer in male patients after neoadjuvant chemoradiation therapy: comparison of long-term outcomes.
    Asoglu O; Tokmak H; Bakir B; Aliyev V; Saglam S; Iscan Y; Bademler S; Meric S
    J Robot Surg; 2020 Jun; 14(3):393-399. PubMed ID: 31313071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
    Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS
    Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Safety and prognosis analysis of transanal total mesorectal excision versus laparoscopic mesorectal excision for mid-low rectal cancer].
    Sun R; Cong L; Qiu HZ; Lin GL; Wu B; Niu BZ; Sun XY; Zhou JL; Xu L; Lu JY; Xiao Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jun; 25(6):522-530. PubMed ID: 35754217
    [No Abstract]   [Full Text] [Related]  

  • 19. Is it time to rethink the rule of total mesorectal excision? A prospective radiological and pathological study in 49 consecutive patients with mid-rectal cancer.
    Guedj N; Zappa M; Maggiori L; Bertin C; Hennequin C; Panis Y
    Colorectal Dis; 2016 Sep; 18(9):O314-21. PubMed ID: 27381492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.